Dow Agrosciences LLC

Eli Lilly and Company

Other

Christopher Stanley Galka

Neil Vincent Kirby

Emily Jane Canada

Mary E Pieczko

Brent Jeffrey Rieder

Maria Angeles Martinez-Grau

Irene Mae Morrison

Chrislyn Marie Carson

Matthew Robert Reinhard

Robert Peter Gajewski

John Gordon Allen

Karin Briner

Zhengyu Huang

John K Swayze

Rebecca L Rezac

Jeannie R Phillips

Michael J Rodriguez

David H Cooper

Erik James Hembre, Ii

Frantz Victor

Andrew Caerwyn Williams

Almudena Rubio

Deyi Zhang

Roger Ryan Rothhaar

Michael Wade Tidwell

Michael Philip Mazanetz

Nicholas Allan Honigschmidt

Gregory M Kemmitt

David D Johnson

Carl P Denny

Gema Ruano Plaza

Marc J McKennon

Steven Armen Boyd

Julie M Miyashiro

Bassam S Nader

David E Podhorez

Gary David Gustafson

Vidyadhar Babu Hegde

Daryl Lynn Smith

Natalia Pokrovskaia

Scott Jerome Bis

Ajay Singh

John Todd Mathieson

Michael Philip Cohen

Richard C Hoying

Richard Edmund Rathmell

Manuel Javier Cases-Thomas

Selma Sapmaz

Jim M Renga

John Cunningham O'Toole

Alicia Marcos Llorente

Sarah Lynne Hellman

Stacy Jo Keding

David G Ouimette

Gary L Sampson

Marta Adeva Bartolome

Jenifer L Adamski

Dave D Johnson

Karen Briner

Christopher Stephen Siedem

Wai-Man Lee

Arundhati S Deo

Michael John Rodriguez

Richard Gerard Conway

The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.

Ghrelin 0-acyl transferase inhibitors

Ghrelin O-acyl transferase inhibitors

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is &#x2014;NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification. 

[object Object]

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where:

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: 

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N&#x2014;R&#x2033;R* where R6 is &#x2014;(CrC3)alkyl-S&#x2014;(C0-C3)alkyl-R10, &#x2014;(C1-C3)alkyl-NR11R12, &#x2014;(CrC3)alkyl-O&#x2014;R13. and other substituents are as defined in the specification. 

The present invention provides novel 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamide compounds with (derivatised) hydroxyalkyl substituents on the pyridine ring, their use as fungicidal compounds, and their use in fungicidal compositions comprising at least one of the 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamide compounds as the active ingredient.

2-methoxyimino-2-(pyridinyloxymethyl) phenyl acetamides with (derivatised) hydroxyalkyl derivatives on the pyridine ring

The present invention provides novel 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamide compounds with polyether substituents on the pyridine ring, their use as fungicidal compounds, and their use in fungicidal compositions comprising at least one of the 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamide compounds as the active ingredient.

2-methoxyimino-2-(pyridinyloxymethyl) phenyl acetamides with polyether derivatives on the pyridine ring

2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamides with (derivatized) hydroxyalkyl derivatives on the pyridine ring

The present invention provides novel 2-methoxyimino-2-(pyridinyloxymethyl) phenyl acetamide compounds with polyether substituents on the pyridine ring, their use as fungicidal compounds, and their use in fungicidal compositions comprising at least one of the 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamide compounds as the active ingredient.

2-methoxyimino-2 (pyrinyloxymethyl) phenyl acetamides with polyether derivatives on the pyridine ring

The present invention provides novel 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamide compounds with substituted ketal substituents on the pyridine ring, their use as fungicidal compounds, and their use in fungicidal compositions comprising at least one of the 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamide compounds as the active ingredient.

2-methoxyimino-2-(pyridinyloxymethyl) phenyl acetamides with substituted ketal derivatives on the pyridine ring

The present invention provides novel 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamide compounds with 5 membered heterocyclic rings on the pyridine ring, their use as fungicidal compounds, and their use in fungicidal compositions comprising at least one of the 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamide compounds as the active ingredient.

2-methoxyimino-2-(pyridinyloxymethyl) phenyl acetamides with 5 membered

The present invention provides novel 2-methoximino-2-(pyridinyloxymethyl)phenyl acetamide compounds with carboxylic acid substituents on the pyridine ring, their use as fungicidal compounds, and their use in fungicidal compositions comprising at least one of the 2-methoximino-2-(pyridinyloxymethyl)phenyl acetamide compounds as the active ingredient.

2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamides with carboxylic

Growing community of inventors

Carmel, IN, United States of America

Christopher Stanley Galka